Format

Send to

Choose Destination
Drug Des Devel Ther. 2018 May 9;12:1183-1193. doi: 10.2147/DDDT.S147104. eCollection 2018.

Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation.

Wang H1,2,3, Wang Y1,2,3, Guo W4, Du B1,2,3, Huang X1,2,3, Wu R1,2,3, Yang B1,2,3, Lin X1,2,3,5, Wu Y6.

Author information

1
Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
2
Stem Cell Research Institute, Fujian Medical University, Fuzhou, People's Republic of China.
3
Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, People's Republic of China.
4
School of Pharmacy, Wenzhou Medical University, Wenzhou, People's Republic of China.
5
Graduate School of Education, Fujian Medical University, Fuzhou, People's Republic of China.
6
School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China.

Abstract

Background:

Mutated anaplastic lymphoma kinase (ALK) drives the development of advanced non-small cell lung cancer (NSCLC). Most reported small-molecule inhibitors targeting the ALK domain do not display good inhibition of the G1202R solvent front mutation. The solvent front mutation was assumed to hinder drug binding. However, a different fact could be uncovered by the simulations reported in this study through a structural analog of alectinib (JH-VIII-157-02), which demonstrated potent effects against the G1202R mutation.

Methods:

Molecular docking, conventional molecular dynamics (MD) simulations, free energy calculations, and umbrella sampling (US) simulations were carried out to make clear the principles of the binding preferences of alectinib and JH-VIII-157-02 toward ALKWT and the ALK G1202R (ALKG1202R) mutation.

Results:

JH-VIII-157-02 has similar binding affinities to both ALKWT and ALKG1202R whereas it has has a much lower binding affinity for alectinib to ALKG1202R. Analysis of individual energy terms indicate the major variation involves the van der Waals and entropy terms. Structural analysis reveals that the conformational change of the ATP-binding glycine-rich loop was primarily responsible for the alectinib resistance, not JH-VIII-157-02. In addition, US simulations prove JH-VIII-157-02 has similar dissociative processes from both ALKWT and ALKG1202R, while alectinib is more easily dissociated from ALKG1202R than from ALKWT, thus indicating lesser residence time.

Conclusion:

Both the binding affinity and the drug residence time should be emphasized in rational drug design to overcome the G1202R solvent front mutation in ALK resistance.

KEYWORDS:

ALK; G1202R; JH-VIII-157-02; alectinib; resistance mechanisms; theoretical study

PMID:
29785088
PMCID:
PMC5953303
DOI:
10.2147/DDDT.S147104
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center